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Abstract
Background Because the injured joint has an actively
inflammatory environment, the survival and repair potential
of cartilage grafts may be influenced by inflammatory pro-
cesses. Understanding the interactions of those processes
with the graft may lead to concepts for pharmacologic or
surgical solutions allowing improved cartilage repair.
Questions/purposes We asked whether the maturation
level of cartilaginous tissues generated in vitro by expanded
human articular chondrocytes (HACs) modulate (1) the
spontaneous production of cytokines and (2) the response
to interleukin (IL)-1b.
Methods Twelve pellets/donor prepared with monolayer-
expanded HACs (n = 6 donors) were evaluated at six
different culture times for mRNA expression (n = 72) and
spontaneous baseline release of monocyte chemoattractant
protein (MCP)-1, IL-8, and transforming growth factor
(TGF)-b1 (n = 72). We cultured 24 pellets/donor from
each of four donors for 1 or 14 days (defined as immature
and mature, respectively) and exposed the pellets to IL-1b
for 3 days. MCP-1, IL-8, TGF-b1, and metalloprotease
(MMP)-1 and MMP-13 were quantified in pellets and
culture supernatants.
Results By increasing culture time, the spontaneous
release of IL-8 and MCP-1 decreased (12.0- and 5.5-fold,
respectively), whereas that of TGF-b1 increased (5.4-fold).
As compared with immature pellets, mature pellets
responded to IL-1b by releasing lower amounts of MMP-1
(2.9-fold) and MMP-13 (1.7-fold) and increased levels of
IL-8, MCP-1, and TGF-b1 (1.5-, 5.0-, and 7.5-fold,
respectively). IL-8 and MCP-1 promptly returned to base-
line on withdrawal of IL-1b.
Conclusions Our observations suggest more mature car-
tilaginous tissues are more resistant to IL-1b exposure and
can activate chemokines required to initiate tissue repair
processes.
Clinical Relevance The implantation of more mature
cartilaginous tissues might provide superior graft survival
and improve/accelerate cartilage repair.
Introduction
Autologous chondrocytes are commonly used as therapeu-
tic agents for the repair of articular cartilage defects [4, 10].
As compared with the transplantation of cell suspension, the
grafting of chondrocyte-loaded three-dimensional biode-
gradable scaffolds immediately after loading (a technique
named matrix-mediated autologous chondrocyte implanta-
tion) [5] or after a certain in vitro maturation time [30, 35]
would hypothetically allow improved handling of the cell
preparation and could offer the possibility of earlier
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postoperative loading. However, it is uncertain whether and
to what extent engineered cartilage should be structurally
and functionally developed before implantation.
Most cell-based cartilage repair techniques require
monolayer expansion of chondrocytes, which is associated
with cell dedifferentiation [1]. It is well established that
dedifferentiated chondrocytes share some phenotypic and
genotypic traits with chondrocytes derived from patients
with osteoarthritis (OA) [2, 39, 49], including expression of
typically fibroblastic markers (eg, versican, Type I colla-
gen, and cathepsin B) [6, 20, 32, 45]. Moreover, similar to
OA chondrocytes, ex vivo-cultured chondrocytes express a
variety of proinflammatory chemokines/chemokine recep-
tors and cartilage degenerative enzymes [8, 9, 13, 15, 36,
48], whose production is enhanced by increasing cell pas-
saging and by stimulation with interleukin (IL)-1b and
tumor necrosis factor-a [17, 26].
IL-1 isoforms have harmful effects on chondrocytes.
They (1) reduce the synthesis of the major physiologic
inhibitors of prodegradative enzymes [31]; (2) stimulate the
production of prostaglandins, free radicals, and nitric oxide
[23]; (3) inhibit the synthesis of matrix components such
as Type II collagen and proteoglycans [19, 31, 42, 46];
(4) induce a dedifferentiated chondrocyte phenotype by
suppressing the expression of Sox-9 [19, 28]; and (5) inhibit
chondrocytes proliferation and induce cell death [28].
These IL-1-mediated effects have particular relevance in
the context of cell-based cartilage repair, considering
therapeutic cell preparations (single-cell suspension, cell-
seeded matrices, or cartilaginous tissues) once grafted in
the joint defect will become exposed to a biochemical
environment that likely contains catabolic mediators
derived from the diseased joint or from the surgical inter-
vention itself, including IL-1b [12, 27, 28]. The presence of
abundant extracellular matrix surrounding the chondro-
cytes in an engineered cartilage graft in principle may
protect the cells from the IL-1 insult. Using native bovine
chondrocytes, Lima et al. [27] recently showed mature
engineered cartilage constructs (having a native level of
glycosaminoglycan [GAG] content and Young’s modulus)
were capable of counteracting IL-1a-mediated catabolic
effects. However, this concept should be investigated using
clinically relevant cells (ie, adult human chondrocytes after
monolayer expansion), which have reduced chondrogenic
capacity as compared with freshly harvested bovine
chondrocytes and typically produce tissues of biochemical
and biomechanical properties inferior to those of native
cartilage.
We asked whether the extent of maturation of human-
based cartilaginous tissues modulates the (1) spontaneous
production of cytokines and (2) the response to IL-1b in
terms of extracellular matrix loss, cytokine, and catabolic
enzyme production.
Materials and Methods
We isolated human articular chondrocytes (HACs) from
cartilage biopsies of six donors and expanded the cells in
monolayer. HACs from all the donors were cultured in
pellets without IL-1b for 3, 6, 9, 15, 21, and 27 days and
analyzed for spontaneous release of IL-8, monocyte che-
moattractant protein (MCP)-1, and transforming growth
factor (TGF)-b1. HACs from four of the six donors were
cultured in pellets for 1 or 14 days (defined as immature
and mature, respectively) and then exposed to IL-1b and
assessed for cartilage matrix loss and production of IL-8,
MCP-1, TGF-b1, metalloprotease (MMP)-1, and MMP-13.
Cytokine production by immature pellets from one of six
donors was also assessed 3 or 7 days after IL-1b with-
drawal (recovery culture) (Fig. 1). IL-8 and MCP-1 are the
most commonly used monocyte and neutrophil chemoat-
tractants, whereas TGF-b1 is one of the main factors
stimulating cartilage matrix production. The selection of
these cytokines and the degradative enzymes investigated
was also based on partially published data [41] that these
were among the most regulated by the process of in vitro
maturation.
Macroscopically normal human articular cartilage sam-
ples (Mankin score 2 to 3) were obtained postmortem
(within 24 hours after death) from the knees of four male
and two female donors (mean age, 44 years; range,
32–65 years) with no clinical history of joint disorders
after informed consent by relatives and in accordance with
the local ethics committee (University Hospital Basel,
Basel, Switzerland).
Cartilage tissues were minced in small pieces and
digested with 22 hours’ incubation at 37C in 0.15%
Type II collagenase (10 mL solution/g tissue, 300 U/mg;
Worthington Biochemical Corp, Lakewood, NJ). The isolated
HACs were plated in tissue culture flasks at 104 cells/cm2
in Dulbecco’s modified Eagle’s medium (DMEM) con-
taining 10% fetal bovine serum, 4.5 mg/mL D-glucose,
0.1 mmol/L nonessential amino acids, 1 mmol/L sodium
pyruvate, 100 mmol/L HEPES buffer, 100 U/mL penicil-
lin, 100 lg/mL streptomycin, and 0.29 mg/mL glutamine
(complete medium) supplemented with 1 ng/mL TGF-b1
and 5 ng/mL fibroblast growth factor-2 (expansion med-
ium) in a humidified 37C/5% CO2 incubator. The growth
factor combination was selected based on the previously
reported ability to increase human chondrocyte prolifera-
tion and capacity to redifferentiate [3, 24].
After approximately 10 days, when cells were approxi-
mately 80% confluent, first-passage cells were rinsed with
phosphate-buffered saline (PBS), detached using 0.05% tryp-
sin/0.53 mmol/L EDTA, and replated at 5 9 103 cells/cm2.
After an additional week, when cells were again approxi-
mately 80% confluent, second-passage cells (corresponding
2774 Francioli et al. Clinical Orthopaedics and Related Research1
123
to a total of 8.1 ± 1.0 doublings) were detached and
induced to redifferentiate in pellet cultures as described
subsequently.
The chondrogenic capacity of expanded chondro-
cytes was investigated in pellet cultures using a defined
serum-free medium, as previously described [28]. Cells
were suspended in DMEM supplemented with ITS + 1
(10 lg/mL insulin, 5.5 mg/mL transferrin, 5 ng/mL sele-
nium, 0.5 mg/mL bovine serum albumin, 4.7 mg/mL
linoleic acid; Sigma-Aldrich Corp, St Louis, MO),
0.1 mmol/L ascorbic acid 2-phosphate, 1.25 mg/mL human
serum albumin, 107 mol/L dexamethasone, and 10 ng/mL
TGF-b1 (chondrogenic medium). Aliquots of 5 9 105 cells/
0.5 mL were centrifuged at 250 9 g for 5 minutes in 1.5-mL
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Fig. 1 Diagram of the experimental design. HACs harvested from six
donors were expanded in monolayer and then cultured in pellets. For
Purpose 1, six donor primaries were used. The total number of pellets
(per donor) was 24, four for each culture time: two were analyzed by
real-time RT-PCR (total number of replicates: 12) and the others by
histology/immunohistochemistry (total number of replicates: 12, not
included in this scheme). ELISA quantification of MCP-1, TGF-b1,
and IL-8 was instead performed in the same supernatants harvested
from two pellets (total number of replicates: 12). For Purpose 2, four
donor primaries were used. The total number of pellets generated per
donor was 48, nine for each group: three were analyzed by RT-PCR,
(total number of replicates: 12) three by biochemical test (GAGs,
DNA, total number of replicates: 12), and three by histology/
immunohistochemistry (not included in this scheme, total number of
replicates: 12). ELISA and Luminex analyses were performed in the
same supernatants harvested from three pellets (total number of
replicates: 12). Differences in the cytokine expression and release,
MMP release, GAG and DNA contents between the indicated groups
(in bold) were assessed using the nonparametric two-tailed Wilcoxon
test. Pellets generated from one donor were also exposed to 3 or
7 days of recovery culture after IL-1 removal. ctr = control (without
IL-1b).
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polypropylene conical tubes (Sarstedt, Nu¨mbrecht,
Germany) to form spherical pellets, which were placed onto
a three-dimensional orbital shaker (Bioblock Scientific,
Frenkendorf, Switzerland) at 30 rpm. Pellets were evalu-
ated for spontaneous release and mRNA expression of
cytokines at different experimental times: 3, 6, 9, 15, 21,
and 27 days; we used six pellets for each time period.
In another experimental set, pellets were cultured for 1
or 14 days (nine pellets for each time period) and then
exposed to 1 ng/mL IL-1b for 3 days [11]. Control pellets
were cultured for 4 or 17 days (nine pellets for each time
period) without IL-1b. Pellets generated with HACs from
one donor were cultured for an additional 3 and 7 days (six
pellets for each time period) in chondrogenic medium after
exposure to IL-1b (recovery culture).
The IL-1b concentration was selected based on a pre-
liminary study [12]. Pellets were processed for histologic,
immunohistochemical, biochemical, and gene expression
analyses, whereas supernatants were collected and evalu-
ated at different time points for cytokines and MMP
release.
Pellets were rinsed with PBS, fixed in 4% formalin for
24 hours, embedded in paraffin, and cross-sectioned (5 lm
thick). Sections were stained with safranin O for sulfated
GAGs [3]. The immunohistochemical analyses for IL-8,
MCP-1, TGF-b1, and Type II collagen were performed
using the following primary antibodies: mouse monoclonal
antihuman IL-8 and TGF-b1 (R&D Systems, Minneapolis,
MN), mouse monoclonal antihuman MCP-1 (PeproTech
Inc, Rocky Hill, NC), and mouse monoclonal antihuman
Type II collagen (II-II6B3; Hybridoma Bank, University of
Iowa, Iowa City, IA). Immunostaining for Type II collagen
was performed as previously described [3, 21]. Tissue
sections for MCP-1 and TGF-b1 were treated with 0.1%
hyaluronidase (Sigma) in PBS at 37C for 10 minutes for
epitope unmasking. After rinsing, slides were incubated for
1 hour at room temperature with primary antibodies diluted
1:10 for both MCP-1 and TGF-b1 in PBS with 1% bovine
serum albumin (BSA). The slides for IL-8 after deparaff-
ination and rehydration were incubated for 1 hour at room
temperature with the primary antibodies diluted 1:10 in
PBS with 1% BSA and then with biotinylated immuno-
globulins against various animal species (Biogenex, San
Ramon, CA) for 20 minutes. Samples were then incubated
with a phosphatase-labeled streptavidin kit (Biogenex) for
20 minutes at room temperature and rinsed. The reactions
were developed using fast red substrate (Biogenex). Neg-
ative controls were performed by omitting the primary
antibody. Slides were counterstained with hematoxylin and
mounted in glycerol gel. Two-three histologic sections for
each condition were visualized with a Nikon Eclipse 90i
microscope equipped with NIS (Nikon Imaging Software)
elements (Nikon Instruments Europe BV, Amstelveen,
The Netherlands).
Pellets were digested in 0.5 mL proteinase K (1 mg/mL
proteinase K in 50 mmol/L Tris with 1 mmol/L EDTA,
1 mmol/L iodoacetamide, and 10 lg/mL pepstatin A) for
15 hours at 56C. GAG amounts were measured spectro-
photometrically after reaction with dimethylmethylene
blue [16] with chondroitin-4-sulfate from bovine trachea
(Sigma-Aldrich Chemie, Buchs San Gallen, Switzerland)
as a standard. The amount of DNA was measured spec-
trofluorometrically using the CyQuant1 Cell Proliferation
Assay Kit (Molecular Probes, Eugene, OR) with calf
thymus DNA as a standard [22].
IL-8 and MCP-1 chemokines were determined by the use
of specific immunoassays standardized in the laboratory of
Istituto Ortopedico Rizzoli Bologna. Briefly, for each cyto-
kine’s determination, two monoclonal antibodies of different
epitope specificity were used to prepare the sandwich
ELISA (IL-8: capture antibody: mouse antihuman IL-8
[Pharmingen, San Diego, CA]; detection antibody: biotin-
ylated mouse antihuman IL-8 [Pharmingen]; MCP-1:
capture antibody: mouse antihuman MCP-1 [Pharmingen];
detection antibody: biotinylated IgG fraction of rabbit anti-
human MCP-1 [Pharmingen]). Ninety-six-well, polystyrene
Table 1. Real-time reverse-transcription PCR primer description
RNA template Primer sequences Annealing temperature Reference
GAPDH 50-TGG TAT CGT GGA AGG ACT CAT GAC
30-ATG CCA GTG AGC TTC CCG TTC AGC
60C Blanco et al. [7]
TGF-b1 50-CTGAGGTATCGCCAGG
30-CGCGTGCTAATGGTGGA
58C PRIMER 3 [38]
IL-8 50-ACTTCTCCACAACCT
30-CCAAACCTTTCCACCC
56C PRIMER 3 [38]
MCP-1 5’-AGCCACCTTCATTCC
3’-GCTTCTTTTGGGACACTTGCT
56C PRIMER 3 [38]
GAPDH = glyceraldehyde-3-phosphate dehydrogenase; TGF-b1 = transforming growth factor-b1; IL-8 = interleukin-8; MCP-1 = monocyte
chemoattractant protein-1.
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Fig. 2A–L Images show the quantification of IL-8, MCP-1, and
TGF-b1 produced/accumulated by HACs at different time of pellet
culture. Amounts of (A) IL-8, (B) MCP-1, and (C) TGF-b1 proteins
are shown, normalized to the DNA contents of the corresponding
pellets, released in the supernatants (six donors, 12 specimens). Real-
time RT-PCR analysis of the expressions of (D) IL-8, (E) MCP-1, and
(F) TGF-b1 mRNA by chondrocytes cultured in pellets at the
different times (four donors, 12 specimens) is shown. Values are
expressed as mean ± SD of measurements. Probability values
(p) versus the 3-day groups are reported on the top of each bar.
n.d. = not detectable. Immunohistologic assessment of representative
pellets cultured for (G–I) 3 days and (J–L) 27 days is shown
(staining with antibodies against [G, J] IL-8, [H, K] MCP-1, and [I,
L] TGF-b1; original magnification, 910). Scale bars = 100 lm.
Results indicate a decrease of IL-8 and MCP-1 and an increase of
TGF-b1 spontaneous production with increasing maturation extent.
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plates (EIA microplate; ICN, Costa Mesa, CA) were coated
with 50 lL purified mouse antihuman IL-8 or MCP-1
adjusted at a concentration of 1 and 4 lg/mL, respectively,
in sodium carbonate buffer pH 9.5 and incubated overnight
at 4C. After washing the plates, serial dilutions of recom-
binant human IL-8 or MCP-1 and appropriate diluted
samples were added to the wells (100 lL/well) and incu-
bated for 2 hours at room temperature followed by a 1-hour
incubation with 100 lL biotinylated mouse antihuman IL-8
or rabbit antihuman MCP-1 per well. After a further
30 minutes’ incubation at room temperature with 100 lL
streptavidin-horseradish peroxidase conjugate per well, the
bound antibodies were detected by adding 1,2-o-phenyl-
enediamine and H2O2 as substrate, running the reaction for
10 minutes before terminating it with 2 mol/L H2SO4, and
the absorbance measured at 492 nm.
TGF-b1 concentrations in supernatants were evaluated
by commercial ELISA kits following the manufacturer’s
instructions (R&D Systems). Values of TGF-b1 measured
in the chondrogenic medium were subtracted from those
measured in the supernatants.
The amount of each released cytokine was normalized to
the DNA content of the tissue and expressed as picogram
per nanogram.
MMPs were quantified in media collected from cultured
pellets by using the MultiAnalyte Profiling MMP Base Kit
(Fluorokine MAP: LMP000) complemented with the spe-
cific MMPs (MMP-1: LMP901; MMP-13: LMP511; R&D
Systems). The assay was performed on a Luminex 100TM
Analyzer (Luminex Corp, Austin, TX) following the
manufacturer’s instructions. The amount of released MMPs
was normalized to the DNA content of the tissue.
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Fig. 3A–J Images illustrate (A–D) histologic and (E–H) immunohis-
tologic assessment of representative pellets maintained in culture for a
total of (A, C, E, G) 4 days (immature) or (B, D, F, H) 17 days
(mature) in which the last 3 days were (A, B, E, F) without IL-1b
(ctr) or (C, D, G, H) with IL-1b ([A–D] safranin O and [E–H] Type II
collagen staining; original magnification, 92). Scale bars = 200 lm.
(I) Sulfated GAG content normalized to the amount of DNA and
(J) DNA content of mature and immature pellets are shown. Values
are expressed as mean ± SD of measurements (four donors, 12
specimens). n.d. = not detectable. Probability values (p) (mature
versus mature [same culture condition] and ctr versus IL-1 [same
culture time]) are reported on the top of the bars. Results indicate a
superior IL-1b-mediated cartilage loss by immature pellets.
2778 Francioli et al. Clinical Orthopaedics and Related Research1
123
RNA was extracted from expanded HACs and from
pellets using 250 lL Trizol1 (Life Technologies, Basel,
Switzerland) according to the manufacturer’s protocol.
RNA was treated with DNAse I using the DNA-freeTM Kit
(Ambion, Austin, TX) and quantified spectrofluorometri-
cally. cDNA was generated from total RNA by using
500 lg/mL random hexamers (Promega AG, Zu¨rich,
Switzerland) and 1 lL 50 U/mL StrataScriptTM reverse
transcriptase (Stratagene, Amsterdam, The Netherlands) in
the presence of dNTPs.
TGF-b1, IL-8, and MCP-1 gene expression was analyzed
by real-time reverse-transcription (RT)-PCR (Table 1)
using glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
housekeeping gene [7]. Real-time PCR was run in a
LightCycler1 Instrument (Roche Molecular Biochemicals,
Mannheim, Germany) using the QuantiTectTM SYBR1
Green PCR Kit (Qiagen, GmbH, Hilden, Germany) with the
following protocol: initial activation of HotStarTaqTM DNA
polymerase at 94C for 15 minutes, 45 cycles of 94C
for 15 seconds, 56 to 60C for 20 seconds, and 72C for
10 seconds. The increase in PCR products was monitored
for each amplification cycle by measuring the increase in
fluorescence caused by the binding of SYBR1 Green I dye
to dsDNA. For each cDNA sample, the threshold cycle (Ct)
value of GAPDH was subtracted from the Ct value of the
target gene to derive DCt. The levels of expression of the
target genes were calculated as 2DCt.
Two-three replicate samples were assessed for each
donor and experimental group. Sample sizes in all groups
compared were equal (Fig. 1). Values are presented as
mean ± SD. Because the assumptions of a parametric test
were not met for data collected for either purpose, we used
a nonparametric two-tailed Wilcoxon test to compare two
matched groups at a given time. For Purpose 1, we deter-
mined differences in the cytokine protein and mRNA
expression levels between Days 6, 9, 15, 21, or 27 and Day
3. For Purpose 2, we determined differences in GAG,
DNA, MMP amounts, and cytokine expression levels
between the following groups: immature without IL-1b
versus mature without IL-1b, immature with IL-1 versus
mature with IL-1, immature without IL-1b versus imma-
ture with IL-1, mature without IL-1b versus mature with
IL-1 (Fig. 1). Statistical evaluation was performed using
SPSS1 Version 7.5 software (SPSS Inc, Chicago, IL).
Results
IL-8 and MCP-1 showed similar secretion kinetics during
pellet culture. The amounts of these cytokines were highest
at Day 3. They decreased (by 3.7- and 3.4-fold, respectively)
after an additional 3 days’ culture and remained close to the
limit of detection after additional culture time. In contrast,
TGF-b1 amounts in the culture medium remained very low
or close to the limit of detection up to 15 days’ culture,
increased at 21 days, and remained at similar levels until
Day 27 (Fig. 2A–C). RT-PCR analyses were in agreement
with the ELISA results: IL-8 and MCP-1 mRNA levels
decreased from 3 to 27 days of culture, respectively, by
22.9- and 5.1-fold, whereas TGF-b1 mRNA increased by
9.6-fold (Fig. 2D–F). Immunohistochemical analysis con-
firmed, as compared with pellets cultured for 3 days, those
cultured for 27 days accumulated lower amounts of IL-8
and MCP-1 and higher amounts of TGF-b1 (Fig. 2G–L).
MMPs release
5.0E-042.0E-02
ctr
IL-1
P = 0.042
P = 0.048
P = 0.035P = 0.028
P = 0.039
P = 0.045
P = 0.041P = 0.038
BA
1.0E-04
2.0E-04
3.0E-04
4.0E-04
5.0E-03
1.0E-02
1.5E-02
P-
1/
DN
A 
(ng
/ng
)
P-
13
/D
NA
 (n
g/n
g)
0.0E+000.0E+00
Immature
(4 days)
Mature
(17 days)
Immature
(4 days)
Mature
(17 days)
M
M
M
M
P
Fig. 4A–B Graphs show the quantification of released MMPs by
HACs. Amounts of (A) MMP-1 and (B) MMP-13 proteins are shown,
normalized to the DNA contents of the corresponding pellets, released
in the supernatants of pellets maintained in culture for a total of 4 days
(immature) or 17 days (mature) in which the last 3 days with IL-1b or
without IL-1b (ctr). Values are expressed as mean ± SD of measure-
ments (four donors, 12 specimens). Probability values (p) (mature
versus mature [same culture condition] and ctr versus IL-1b [same
culture time]) are reported on the top of the bars. Results indicate a
superior IL-1b-mediated MMPs production by immature pellets.
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IL-1b exposure to immature pellets caused an extensive
loss of cartilaginous matrix as evidenced (immuno)histo-
logically by absence of GAG and Type II collagen staining
(Fig. 3A–H) and biochemically by a reduction of GAG to
undetectable levels (Fig. 3I). In mature pellets, IL-1b
exposure also caused a loss of cartilaginous components
(GAG content reduced by 1.7-fold). DNA contents were,
instead, unaffected by IL-1b exposure (Fig. 3 J). All the
cell primaries tested in this study (independently from
donors’ age) similarly responded to IL-1b. In both imma-
ture and mature pellets, the exposure to IL-1b increased the
release of MMP-1 (6.7- and 3.2-fold, respectively) and
MMP-13 (9.3- and 2.8-fold, respectively). However, the
amounts of both degradative enzymes after IL-1b exposure
were higher in the media from immature versus mature
pellets (2.1- and 2.0-fold, respectively, for MMP-1 and
MMP-13) (Fig. 4). Stimulation with IL-1b drastically
enhanced the release of IL-8 and MCP-1. Mature tissues
responded to IL-1b by releasing higher amounts of both
chemokines so that the final amounts of IL-8 and MCP-1 in
the supernatants of such pellets were 1.5- and 5.0-fold
higher than those of immature pellets. TGF-b1 release was
also enhanced to a higher extent by mature pellets in
response to IL-1b; the amount of this cytokine was 6.2-fold
higher in the supernatants of mature versus immature pel-
lets (Fig. 5A–C). RT-PCR results were in general
agreement with ELISA results. Stimulation with IL-1b
caused an upregulation of IL-8 and MCP-1 mRNA
expression that was more pronounced in mature tissues.
Consequently, IL-8 and MCP-1 mRNA expression were,
respectively, 1.8- and 28.0-fold higher expressed in mature
versus immature tissues. TGF-b1 mRNA expression was
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Fig. 5A–F Graphs show the quantification of IL-8, MCP-1, and
TGF-b1 produced by HACs. Amounts of (A) IL-8, (B) MCP-1, and
(C) TGF-b1 are shown, normalized to the DNA contents of the
corresponding pellets, released in the supernatants of tissues main-
tained in culture for a total of 4 days (immature) or 17 days (mature)
in which the last 3 days were with IL-1b or without IL-1b (ctr). Real-
time RT-PCR analysis of the expression of (D) IL-8, (E) MCP-1, and
(F) TGF-b1 mRNA by chondrocytes cultured in pellets at the
different times is shown. Values are expressed as mean ± SD of
measurements (four donors, 12 specimens). n.d. = not detectable.
Probability values (p) (mature versus mature [same culture condition]
and ctr versus IL-1b [same culture time]) are reported on the top of
the bars. Results indicate a superior IL-1b-mediated production of
IL-8, MCP-1, and TGF-b1 by immature pellets.
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only slightly increased after IL-1b stimulation (Fig. 5D–F)
in both mature and immature tissues. The intensity of
staining for IL-8 and MCP-1 increased in both mature and
immature tissues after IL-1b exposure (Fig. 6). The
amounts of IL-8 and MCP-1 released by mature pellets
strongly decreased (by 2.3- and 1.8-fold, respectively) after
3 days of recovery culture and reached levels measured
before IL-1b exposure after 7 days of recovery culture.
TGF-b1, instead, further increased by 5.8-fold after 3 days
of recovery culture and then remained at similar levels at
7 days of recovery culture (Table 2).
Discussion
Chondrocyte interactions with inflammatory processes have
been reported in native cartilage and freshly isolated
chondrocytes of animal origin but not during chondrogenesis
of expanded HACs. We therefore investigated whether and
how the extent of maturation of cartilaginous tissues gener-
ated in vitro by monolayer-expanded HACs modulates the
profile of chemokine production and the inflammatory/
catabolic response to IL-1b.
Some limitations of this study must be considered. First,
we investigated only a limited number of cytokines, and
anabolic factors could show a different expression pattern.
However, we selected what are considered to be the most
relevant factors involved in cartilage anabolic and inflam-
matory processes. Second, we quantified only the amounts
of MMP-1 and MMP-13 and thus could not exclude the
involvement of other relevant proteases such as aggrecan-
ase (ADAMTS-4, 5) in the observed IL-1b-mediated
matrix reduction. Third, IL-1b was supplemented in cells
cultured with medium containing dexamethasone and
TGF-b1, necessary to maintain the chondrocytic phenotype
[18] in pellet culture, and it is thus possible some of the
observed effects can be partially mediated by these factors
[29]. Fourth, the production of the investigated chemokines
by monolayer-expanded HACs might differ using a model
system different from the one implemented in this study
(ie, high-density culture in the presence of TGF-b) and in
an in vivo situation. In the absence of an alternative
orthotopic model in which to test the performance of
human chondrocytes for cartilage repair, further studies
would be necessary to investigate the HAC performance
under conditions better resembling the injured joint (eg,
more physiologic oxygen tension, exposure to loading,
coculture with mesenchymal progenitor cells).
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Fig. 6A–H Images illustrate the accumulation of (A–D) IL-8 and
(E–H) MCP-1 in the tissues. Immunohistologic assessment of
representative pellets maintained in culture for a total of (A, C, E,
G) 4 days (immature) or (B, D, F, H) 17 days (mature) in which the
last 3 days were (A, B, E, F) without IL-1b (ctr) or (C, D, G, H) with
IL-1b is shown (staining with antibodies against [A–D] IL-8 and [E–
H] TGF-b1; original magnification, 920 for pictures and 940 for
inserts). Scale bars = 50 lm.
Table 2. Amounts of IL-8, MCP-1, and TGF-b1 released during
recovery culture of mature pellets
Conditions Amount released (pg/ng)*
IL-8 MCP-1 TGF-b1
IL-1b 11.31 ± 0.92 20.84 ± 1.89 0.01 ± 0.00
3 days 4.93 ± 0.41 1.23 ± 0.10 0.36 ± 0.02
7 days 0.04 ± 0.01 0.32 ± 0.02 0.33 ± 0.03
* The amounts of cytokines are normalized to the DNA contents
of corresponding pellets and presented as delta between baseline
(control) values; values are expressed as mean ± SD; IL-8 = inter-
leukin-8; MCP-1 = monocyte chemoattractant protein-1; TGF-b1 =
transforming growth factor-b1; IL-1b = interleukin-1b.
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Several studies suggest unstimulated cultured chondro-
cytes produce various chemokines involved in the
recruitment of inflammatory cells [13, 33, 48]. However, it
is unclear whether HACs at different stages of in vitro
redifferentiation express differing levels of chemokines.
Our finding that IL-8 and MCP-1 mRNA expression and
protein release by HACs decreased whereas TGF-b1
mRNA and protein increased with increasing culture time
indicates, under ‘‘unstressed’’ conditions (ie, absence of
IL-1b), the more mature engineered grafts have the pro-
pensity to reduce inflammatory signals and to boost
anabolic processes.
The responses of HACs to such proinflammatory cyto-
kines have been investigated by several scientists [26, 40] to
mimic processes occurring in degenerative cartilage dis-
eases. It appears such molecules enhance the expression of a
large number of mediators contributing to cartilage degra-
dation such as MMPs [17, 33] and inflammatory cytokines
[29, 44] and reduce the synthesis of key extracellular matrix
proteins such as Type II collagen and proteoglycans [19, 31,
42, 46, 47]. For such studies, however, primary undifferen-
tiated chondrocytes or cartilage explants derived from
patients with OA have so far been used. Because the
responses of chondrocytes to IL-1 isoforms vary from
normal versus osteoarthritic chondrocytes and from differ-
entiated versus passaged chondrocytes [26], the results
reported in the aforementioned studies cannot be directly
translated to a cell-based clinical scenario. In our study,
treatment for 3 days with IL-1b mimics the duration of the
inflammation caused by the surgical intervention and could
thus be relevant to predict some traits of the response of
chondrocyte-based grafts to the inflamed cartilage defects.
We observed IL-1b treatment caused a reduction in the
amount of cartilaginous matrix, which was more pronounced
in the immature tissues compared with the mature ones.
These results might be the consequence of an enhanced tis-
sue degradation mediated by MMPs: our data show IL-1b
treatment increased production of MMP-1 and MMP-13 that
was more pronounced in immature pellets. Although the
functional activity of such MMPs in our study was not
assessed, previous studies reported it may be enhanced by
IL-1b [17, 25, 43]. Mature pellets (versus immature pellets)
responded to IL-1b by expressing higher amounts of IL-8
and MCP-1 mRNA and releasing a larger amount of these
two chemokines. Importantly, the production of IL-8 and
MCP-1 was not chronic but strongly reduced a few days after
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Predicted processes activated by the grafting of engineered mature
cartilaginous tissues in the cartilage defect
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Fig. 7A–C Schematic view of the hypothesis and results is shown.
(A) During the in vitro maturation (in the absence of IL-1b),
chondrocyte-based constructs accumulate a large amount of cartilag-
inous matrix (dark gray) and express/release lower amounts of IL-8
and MCP-1 and higher amounts of TGF-b1. (B) When implanted in
the cartilage defect, mature grafts respond to IL-1b by losing some of
the accumulated cartilage matrix (light gray) and enhancing the
expression/release of IL-8 and MCP-1 in a transient manner and of
TGF-b1. (C) IL-8 and MCP-1 would attract neutrophils, monocytes,
and chondroprogenitors from the surrounding tissues. Although the
former cells would induce tissue remodeling, the chondroprogenitors,
especially in the presence of elevated concentration of TGF-b1,
would contribute to the deposition of extracellular matrix. Taken
together, the contribution of the different recruited cell types would
improve/accelerate cartilage repair processes (see dashed arrow), and
the transient nature of the enhanced release of IL-8 and MCP-1 would
not induce chronic inflammation processes.
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IL-1b withdrawal. The transient release of these chemokines
would support recruitment to the grafted area not only of
monocytes and neutrophils but also of chondroprogenitor
cells [14, 34, 37], possibly resulting in a controlled activation
of inflammatory-mediated repair processes (Fig. 7).
In conclusion, the cytokine expression profile and
response to IL-1b by HACs are modulated by their dif-
ferentiation stage. Engineered tissues with higher extent of
maturation after IL-1b treatment (1) better preserve the
deposited cartilaginous matrix, (2) release lower amounts
of MMPs, and (3) transiently release higher amounts of
proinflammatory and chondrogenic chemokines. Our find-
ings suggest more mature cartilaginous tissues might be
more resistant to IL-1b exposure and more efficiently
recruit/commit cells typically involved in tissue repair
processes (Fig. 7).
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